Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To compare the overall survival (OS) of patients treated with E7389 versus the Treatment of Physician’s Choice (including anti-tumor treatment of the investigator’s choice and palliative treatment) in patients with locally recurrent or metastatic breast cancer, who have received 2-5 prior chemotherapy regimens, which must have included an anthracycline and a taxane as prior therapy and at least 2 of which must have been given for locally recurrent or metastatic disease. Patients must also be refractory to their latest chemotherapy regimen, documented by progression on or within six (6) months of therapy.
Critère d'inclusion
- Locally recurrent or metastatic breast cancer after failure of multiple prior chemotherapy regimens